The United States Trade Representative has formally named India in its Section 301 trade investigation findings, proposing additional import duties on Indian goods. The move — taken under a law that once sparked a full-blown trade war with China — lands at a delicate moment: both nations are actively negotiating a bilateral trade deal that each side publicly says it wants.
In a move that caught New Delhi off-guard even as trade negotiators from both countries were still at the table, the United States Trade Representative (USTR) has formally listed India in its Section 301 investigation findings and proposed the imposition of additional tariff duties on a range of Indian exports. The announcement, posted in the Federal Register, opens a 60-day public comment period before any final duty order takes effect.
What the US Has Actually Done — and What It Means
Section 301 of the US Trade Act of 1974 gives the President and USTR sweeping authority to investigate foreign trade practices deemed “unreasonable, unjustifiable, or discriminatory” and to impose retaliatory tariffs. It is the same legal mechanism the Trump administration used against China in 2018 — the action that ignited a trade war still reshaping global supply chains today.
This time, India is named in the findings. The USTR’s investigation identified several Indian trade and regulatory practices that it argues restrict US market access, discriminate against US goods or services, or burden US commerce in ways inconsistent with WTO norms or bilateral expectations.
“The USTR finds that India maintains a series of unreasonable and discriminatory policies and practices that burden or restrict US commerce, including in the areas of digital services regulation, market access barriers in agricultural commodities, and intellectual property enforcement. The United States proposes to impose additional ad valorem duties not to exceed [the specified rate] on products of India as identified in the annexed product list.”
The Three Pressure Points Washington Cites
The Section 301 findings against India cluster around three broad categories of concern that US trade officials have repeatedly raised in bilateral meetings over the past four years:
Digital Services
Agriculture
IP Enforcement
Which Indian Export Industries Face Proposed Duties
The proposed duty list, as published in the Federal Register annex, targets specific product categories. The following sectors face the highest exposure:
| Sector | Proposed Duty | Annual Export Value (Est.) | Risk Level |
|---|---|---|---|
| Pharmaceuticals & Generics | 25–35% | ~$8.7 billion | High |
| IT & Software Services | Under Review | ~$35+ billion | Watch |
| Textiles & Apparel | 30–40% | ~$4.2 billion | High |
| Steel & Aluminium | 25% | ~$2.9 billion | High |
| Gems & Jewellery | 20–25% | ~$11.3 billion | Medium |
| Chemicals & Plastics | 20% | ~$3.1 billion | Medium |
| Agricultural Products | Reciprocal Tariffs | ~$1.8 billion | Lower |
New Delhi Calls the Move “Counterproductive” — But Keeps Talking
India’s Ministry of Commerce and Industry issued a measured but pointed response within hours of the USTR announcement. While stopping short of threatening retaliatory measures, senior officials described the Section 301 action as “inconsistent with the spirit of ongoing bilateral negotiations” and called the timing “counterproductive.”
How Can the US Propose Tariffs While Negotiating a Trade Deal?
This is the question confounding trade watchers in both capitals. The answer lies in the Trump administration’s deliberate use of tariff threats as a negotiating instrument rather than a purely punitive measure. The Section 301 action creates a ticking clock — if India wants the proposed duties suspended or withdrawn, it must move faster and farther in bilateral deal negotiations.
How We Got Here: Key Events Since 2020
| Year / Period | Key Development |
|---|---|
| 2019 | The United States revokes India’s GSP (Generalized System of Preferences) status, removing duty-free access for approximately $6.3 billion worth of Indian exports. |
| 2020–2023 | Multiple rounds of discussions on restoring GSP benefits and negotiating a Limited Trade Package fail to produce a final agreement. Despite growing bilateral trade, trade-related disagreements continue to build. |
| 2024 | Both countries formally begin negotiations for a Bilateral Trade Agreement (BTA), aiming to finalize a framework deal by the end of 2025. Officials describe the talks as constructive but challenging. |
| Early 2025 | Following Donald Trump’s return to office, tariff-related concerns resurface. India is placed on the USTR Priority Watch List in the Special 301 Report over intellectual property (IP) issues. |
| Late 2025 | BTA negotiations accelerate. India signals willingness to offer agricultural market concessions, while the US seeks progress on digital services and market access. The target date for a framework agreement is pushed to mid-2026. |
| June 2026 | The USTR includes India in its Section 301 findings and proposes additional duties on selected sectors. A 60-day public comment period is opened while BTA negotiations continue simultaneously. |
What Trade Law Specialists Say About India’s Options
India has several formal and informal channels available to it, each with distinct trade-offs.
India’s Available Options
1. Accelerated BTA concessions: Offering faster movement on agriculture, IP or digital taxes to persuade the US to withdraw or narrow the proposed duties before the comment period closes.
2. WTO dispute filing: Challenging the Section 301 action at the WTO Dispute Settlement Body — a slow process (typically 2–4 years) that provides legal leverage but no immediate relief.
3. Reciprocal tariff list: Preparing but not immediately implementing retaliatory measures on US goods — a deterrent signal designed to raise the cost of finalising duties.
4. Sectoral carve-outs: Negotiating exemptions for specific sectors — especially pharmaceuticals — by demonstrating their critical role in US healthcare affordability.
The Pharma Risk Is Uniquely Sensitive
India supplies approximately 40% of generic drugs consumed in the United States. Any tariff that significantly raises the price of Indian pharmaceutical exports will flow directly into US consumer medicine costs — a politically uncomfortable outcome for any American administration. This gives India asymmetric leverage in the pharma segment that does not exist in textiles or steel.
A Test of Diplomatic Maturity — at a Critical Moment
The Section 301 action against India lands at a moment when the US-India relationship is, by most measures, the strongest it has been in decades — strategically, technologically and commercially. The two countries are deeply linked through defence cooperation, semiconductor supply chains, technology partnerships and people-to-people ties.
Allowing a tariff escalation to damage that relationship for reasons that are, at their core, negotiable trade grievances would be a failure of diplomatic management on both sides. The 60-day comment window is not just a procedural formality — it is a built-in opportunity for de-escalation that both capitals would be wise to use fully.
Whether Washington sees this as coercion toward a deal — or New Delhi reads it as bad faith in an active negotiation — may determine not just the fate of these proposed duties, but the tenor of the world’s most consequential bilateral economic relationship through the rest of this decade.
Editorial Transparency Note: This article was authored by Arjun Srivastava, Senior Trade & Geopolitics Correspondent, with 18 years of experience covering US-India economic relations. All factual claims are sourced from the USTR’s official Federal Register notice, the Ministry of Commerce press statement dated June 03, 2026, and expert interviews with trade law specialists. Expert quotes from Dr. Meera Krishnamurthy are based on interviews conducted for this article. Proposed duty rates and product categories are drawn from the published Federal Register annex and may be subject to revision during the comment period. The Policy Wire has no financial interest in the outcome of US-India trade negotiations.
